Professor Hui K. Gan
(MBBS, FRACP, PhD)
Prof Hui Gan is a medical oncologist at Austin Health (Melbourne, Australia) where he specializes in primary brain tumours and Phase 1 clinical trials. He is the Medical Director of the Cancer Clinical Trials Unit at Austin Health. He is Chair of the Scientific Advisory Committee of Cooperative Trials Group for Neuro-Oncology (COGNO).
Prof Gan is also a clinician-scientist at the Olivia Newton-John Cancer Research Institute (ONJCRI) where he leads a translational research group (the Cancer Therapies and Biology Group) as well as being the Co-Director of the ONJCRI Centre for Research Excellence for Brain Cancer.
His group is primarily focused on developing better therapies for rare cancers such as brain tumours, including a strong focus on antibody-based therapies against EGFR and other member of the ErbB family. He has been involved in the development of drugs in brain cancer including depatuxizumab mafodotin and ifabotuzumab.
Current Projects & Areas of Interest:
Clinical trials for novel drugs for patients with primary brain cancer
Both industry and investigator initiated clinical trials
Precision oncology and other novel trial approaches
Preclinical and clinical research of the biology and therapeutic targeting
ErbB family, including novel drugs against tumour specific, conformation targeting drugs such as depatuxizumab mafodotin
Tumour microenvironment targeting, especially EphA3 targeting utilizing drugs based on ifabotuzumab
Non-invasive methods of tumour assessment including novel drug and imaging-based modalities